Sirona Biochem Corp. Stock
-
Your prediction
Pros and Cons of Sirona Biochem Corp. in the next few years
Pros
Cons
Performance of Sirona Biochem Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Sirona Biochem Corp. | - | - | - | - | - | - | - |
Satellos Bioscience Inc. | 3.930% | -5.743% | 25.263% | 9.174% | -15.000% | 99.163% | - |
Vaxart Inc. | 2.420% | -17.875% | -15.226% | -64.725% | -61.009% | -85.294% | -94.994% |
Larimar Therapeutics Inc. | 0.000% | -0.556% | 7.831% | -49.930% | -3.763% | 14.744% | -77.255% |
Comments
News

Dentsply Sirona (XRAY) Q2 Sales Drop 5%
Dentsply Sirona (NASDAQ:XRAY), a major player in dental products and technologies, released its second quarter results on August 7, 2025. The company reported GAAP revenue of $936 million and

Sirona Biochem Announces Debenture Financing
VANCOUVER, British Columbia, April 22, 2025 -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) is pleased to announce a non-brokered private placement

Sirona Biochem Secures Strategic Investment Agreements and New Joint Venture with Promura GmbH
Vancouver, British Columbia – April 22, 2025 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”), a biotechnology company specializing cosmetic ingredients and new drug